QURE
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-210, a product candidate for the treatment of Parkinson's disease; AMT-260 for temporal lobe epilepsy; AMT-240, a preclinical product candidate for the treatment of autosomal dominant Alzheimer's disease; and AMT-161 for the treatment of amyotrophic lateral sclerosis. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
uniQure N.V. (QURE) is rated C- (2.0/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Growth (B+); its weakest is Revisions (F). The rating has held at C- for 2 weeks.
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-14 | C (2.5) | B+ (3.6) | C- (2.1) | D+ (1.6) | F (0.0) | C- (2.0) |
| 2026-11-07 | C+ (2.5) | B (3.3) | C- (2.0) | D+ (1.6) | F (0.0) | C- (1.9) |
| 2026-10-31 | C (2.4) | B (3.3) | C- (2.1) | C- (2.0) | F (0.0) | C- (2.0) |
| 2026-10-24 | C (2.5) | B (3.3) | C- (2.1) | C+ (2.6) | C+ (2.6) | C+ (2.6) |
| 2026-10-17 | C+ (2.5) | B (3.3) | C- (2.1) | C+ (2.7) | C+ (2.6) | C+ (2.6) |